Vandetanib

Generic Name: Vandetanib

Brand Names: Caprelsa

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄BrFN_₄O_₂

CAS Number: 443913-73-3

Unique Ingredient Identifier: YO460OQ37K

Background: Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

Indication: Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

Associated Conditions: Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer

Clinical Trials

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Ureter Cancer
Urethral Cancer

Interventions: Drug: carboplatin
Drug: gemcitabine hydrochloride
Drug: Placebo
Drug: vandetanib

First Posted Date: 2010-08-31

Last Posted Date: 2019-05-16

Lead Sponsor: Cardiff University

Target Recruit Count: 82

Registration Number: NCT01191892

Locations: 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
🇬🇧
Royal Bournemouth General Hospital, Bournemouth, United Kingdom
🇬🇧
Royal Surrey County Hospital, Surrey, United Kingdom

and more 18 locations

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

Phase 1

Completed

Conditions: Cancer of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Cancer of the Stomach

Interventions: Drug: Vandetanib
Drug: 5 Fluorouracil (FU)
Drug: Carboplatin
Drug: Paclitaxel
Radiation: External Beam Radiation Therapy (RT)

First Posted Date: 2010-08-17

Last Posted Date: 2021-01-22

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 9

Registration Number: NCT01183559

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

Phase 1

Completed

Conditions: Diffuse Intrinsic Pontine Glioma

Interventions: Drug: vandetanib and dasatinib

First Posted Date: 2009-10-16

Last Posted Date: 2015-04-06

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 25

Registration Number: NCT00996723

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Breast Cancer
Head and Neck Cancer
Prostate Cancer
Lung Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: docetaxel
Drug: vandetanib
Genetic: proteomic profiling
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2009-07-13

Last Posted Date: 2017-04-24

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00937417

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Phase 1

Terminated

Conditions: Medullary Thyroid Carcinoma

Interventions: Drug: Bortezomib
Drug: Vandetanib

First Posted Date: 2009-06-18

Last Posted Date: 2018-11-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT00923247

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Carcinoma

Interventions: Drug: Docetaxel
Drug: Placebo
Drug: vandetanib

First Posted Date: 2009-04-13

Last Posted Date: 2018-09-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 149

Registration Number: NCT00880334

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: docetaxel
Drug: vandetanib

First Posted Date: 2009-04-01

Last Posted Date: 2016-12-19

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 129

Registration Number: NCT00872989

Locations: 🇺🇸
Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸
Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States
🇺🇸
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States

and more 134 locations

Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Vandetanib

First Posted Date: 2009-03-17

Last Posted Date: 2016-10-10

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 15

Registration Number: NCT00862836

Locations: 🇩🇪
Research Site, Berlin, Germany

Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas

Phase 1

Completed

Conditions: Malignant Gliomas

Interventions: Drug: Vandetanib
Radiation: Fractionated Stereotactic Radiotherapy

First Posted Date: 2009-01-15

Last Posted Date: 2013-06-26

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 13

Registration Number: NCT00822887

Locations: 🇺🇸
University of Colorado Health Science Center, Aurora, Colorado, United States

Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma

Interventions: Drug: Sirolimus
Drug: Vandetanib

First Posted Date: 2009-01-13

Last Posted Date: 2015-05-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 33

Registration Number: NCT00821080

Locations: 🇺🇸
Dana-Farber Cancer Instiute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy